Emily McCracken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emily McCracken has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Raquel Langdon
George Washington University School of Medicine, Children’s National Hospital, Washington, DC, USA
3 shared publications - Alexandra B. Kornbluh
Children's National Hospital
2 shared publications - Elizabeth Pickup
Children's National Hospital
2 shared publications - Jeffrey Strelzik
Division of Neurology, The George Washington University/Children's National Hospital, Washington, DC, USA
2 shared publications Marc DiSabella
2 shared publications- Marc DiSabella
Division of Neurology, The George Washington University/Children's National Hospital, Washington, DC, USA
2 shared publications
Latest Publications
- 9 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 85-91
Onabotulinumtoxin A is an effective preventative treatment of chronic and daily pediatric migraine
- 9 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 85-91
Onabotulinumtoxin A is an effective preventative treatment of chronic and daily pediatric migraine
- Open Access
- 19 June 2026
- Published by Elsevier in SSRN Electronic Journal
Peripheral Nerve Blocks in the Treatment of Pediatric Headaches
Background: Peripheral nerve blocks (PNBs), while an effective treatment of headache disorders in adults, have been infrequently studied in pediatric patients. This study aimed to assess practice patterns in PNB use in pediatric headache.Methods: This was a prospective study conducted between 2020 and 2022 in a headache clinic at a tertiary children’s hospital. Pre- and post-injection survey data were prospectively obtained from 16 patients over 32 visits where PNBs, including greater and lesser occipital, auriculotemporal, supraorbital, and supratrochlear nerve blocks, were administered.Results: Participants ranged in age from 10 to 19 years old, with a median age of 16.7 years, and the majority were diagnosed with migraine without aura. Among the total cohort, mean pain scores, obtained on a 10-point scale, decreased from 4.4 pre-injection to 2.8 post-injection (p=0.003). When stratified by specific headache diagnosis, only patients with migraine without aura reported significant pain decrease (p=0.007).Conclusion: These preliminary findings support that PNBs may be a promising treatment in pediatric headache, particularly in migraine without aura.
- 19 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPeripheral Nerve Blocks in the Treatment of Pediatric Headaches
Background: Peripheral nerve blocks (PNBs), while an effective treatment of headache disorders in adults, have been infrequently studied in pediatric patients. This study aimed to assess practice patterns in PNB use in pediatric headache.Methods: This was a prospective study conducted between 2020 and 2022 in a headache clinic at a tertiary children’s hospital. Pre- and post-injection survey data were prospectively obtained from 16 patients over 32 visits where PNBs, including greater and lesser occipital, auriculotemporal, supraorbital, and supratrochlear nerve blocks, were administered.Results: Participants ranged in age from 10 to 19 years old, with a median age of 16.7 years, and the majority were diagnosed with migraine without aura. Among the total cohort, mean pain scores, obtained on a 10-point scale, decreased from 4.4 pre-injection to 2.8 post-injection (p=0.003). When stratified by specific headache diagnosis, only patients with migraine without aura reported significant pain decrease (p=0.007).Conclusion: These preliminary findings support that PNBs may be a promising treatment in pediatric headache, particularly in migraine without aura.
- Open Access
- 24 August 2022
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 37 (10-11) , 871-881
Pediatric Headache Experience During the COVID-19 Pandemic
Objective: Headache disorders are exceedingly common in children and adolescents. The association between headaches, emotional stress, and disruptions in daily routines are well established. The goal of this study is to compare the experiences of patients with a preexisting diagnosis of a primary headache disorder in terms of headache frequency and severity, lifestyle techniques for headache prevention, screen use, and mood from before and after the onset of the COVID-19 pandemic. Methods: Patients evaluated by the Headache Clinic at Children’s National Hospital between Summer 2020 and Winter 2021 were enrolled in a patient registry. Patients completed a questionnaire examining changes in headache characteristics and lifestyle factors since the onset of the COVID-19 pandemic. Results: A total of 107 patients completed the survey. Since the pandemic’s onset, patients reported decreased physical activity (n = 59, 55%), increased frequency of chronic headaches from 40% (N = 42) to 50% (N = 54), and increased constant daily headaches from 22% (n = 24) to 36% (n = 38). Patients reported worsened anxiety (n = 58, 54%), mood (n = 50, 47%), and workload (n = 49, 46%). Sixty-one percent (n = 65) of patients reported using screens for school for more than 6 hours per day. The majority (n = 67, 63%) of patients indicated that they would prefer attending in-person school, with 14% (n = 15) responding that they preferred online school. Conclusion: Since the COVID-19 pandemic’s onset, pediatric headache patients have experienced increasing headache frequency, worsening anxiety and mood, decreased physical activity, and increased screen usage. Although this study is limited by sample size and observational design, future population-based studies will further elucidate the impact of this pandemic on pediatric headache.
- 24 August 2022
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 37 (10-11) , 871-881
Open AccessPediatric Headache Experience During the COVID-19 Pandemic
Objective: Headache disorders are exceedingly common in children and adolescents. The association between headaches, emotional stress, and disruptions in daily routines are well established. The goal of this study is to compare the experiences of patients with a preexisting diagnosis of a primary headache disorder in terms of headache frequency and severity, lifestyle techniques for headache prevention, screen use, and mood from before and after the onset of the COVID-19 pandemic. Methods: Patients evaluated by the Headache Clinic at Children’s National Hospital between Summer 2020 and Winter 2021 were enrolled in a patient registry. Patients completed a questionnaire examining changes in headache characteristics and lifestyle factors since the onset of the COVID-19 pandemic. Results: A total of 107 patients completed the survey. Since the pandemic’s onset, patients reported decreased physical activity (n = 59, 55%), increased frequency of chronic headaches from 40% (N = 42) to 50% (N = 54), and increased constant daily headaches from 22% (n = 24) to 36% (n = 38). Patients reported worsened anxiety (n = 58, 54%), mood (n = 50, 47%), and workload (n = 49, 46%). Sixty-one percent (n = 65) of patients reported using screens for school for more than 6 hours per day. The majority (n = 67, 63%) of patients indicated that they would prefer attending in-person school, with 14% (n = 15) responding that they preferred online school. Conclusion: Since the COVID-19 pandemic’s onset, pediatric headache patients have experienced increasing headache frequency, worsening anxiety and mood, decreased physical activity, and increased screen usage. Although this study is limited by sample size and observational design, future population-based studies will further elucidate the impact of this pandemic on pediatric headache.
- 18 July 2022
- Published by SAGE Publications in Cephalalgia
- Vol. 42 (13) , 1349-1358
Pediatric screen exposure and school related headache disability
Background and Objectives: Prolonged screen exposure is often cited as a trigger for pediatric headache. We present initial findings evaluating the association between adolescent screen use type, duration, and school disability.Methods: New patients aged 12–17 years presenting to a headache clinic were screened and surveyed regarding headache characteristics, behavioral habits, school attendance, and screen utilization.Results: 99 adolescents (29 M, 70 F) with average age 14.8 years and average headache frequency of 17 days per month completed the survey. Patients missed an average of five full days and three partial days of school due to headaches over the 90 days prior to survey completion. No statistically significant correlation was found between type or duration of screen exposure and monthly headache frequency, school attendance, or school functioning. A small positive association was seen between increasing duration of computer use, total hours screen use, and school absenteeism. While most adolescents reported prolonged screen use (58.6%) and luminosity (64.6%) worsened headaches, no statistical difference was seen in average number of headache days per month.Conclusions: Average monthly headache frequency in an adolescent population was not significantly correlated with type or duration of screen exposure. Further studies are needed to elucidate how screen utilization impacts school related headache disability.
- 18 July 2022
- Published by SAGE Publications in Cephalalgia
- Vol. 42 (13) , 1349-1358
Pediatric screen exposure and school related headache disability
Background and Objectives: Prolonged screen exposure is often cited as a trigger for pediatric headache. We present initial findings evaluating the association between adolescent screen use type, duration, and school disability.Methods: New patients aged 12–17 years presenting to a headache clinic were screened and surveyed regarding headache characteristics, behavioral habits, school attendance, and screen utilization.Results: 99 adolescents (29 M, 70 F) with average age 14.8 years and average headache frequency of 17 days per month completed the survey. Patients missed an average of five full days and three partial days of school due to headaches over the 90 days prior to survey completion. No statistically significant correlation was found between type or duration of screen exposure and monthly headache frequency, school attendance, or school functioning. A small positive association was seen between increasing duration of computer use, total hours screen use, and school absenteeism. While most adolescents reported prolonged screen use (58.6%) and luminosity (64.6%) worsened headaches, no statistical difference was seen in average number of headache days per month.Conclusions: Average monthly headache frequency in an adolescent population was not significantly correlated with type or duration of screen exposure. Further studies are needed to elucidate how screen utilization impacts school related headache disability.
- 15 February 2022
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 23 (9) , 1536-1543
Natural History of Abortive Medication Withdrawal in the Management of Pediatric Medication Overuse Headache
Objective: The objective of this study is to document pain scores during withdrawal of abortive medication in patients diagnosed with medication overuse headache. Design: Cross-sectional study. Setting: Children’s National Hospital’s Headache Program. Subjects: Patients 6–18 years of age who presented to the Headache Clinic at Children’s National Hospital with presumed medication overuse headache between March 2017 and March 2019 were invited to participate. Methods: Patients were instructed to abruptly discontinue overused medications and record their headache characteristics daily in a diary for 8 weeks. Results: Fourteen diaries were returned and analyzed at a 4-week follow-up visit. Ninety-three percent of the patients were females, with a median age of 14.9 years (standard deviation [SD] = 2.0). The average headache intensity upon study entry was 4.7 out of 10 (SD = 2.5), and the average headache intensity upon study completion was 3.1 (SD = 2.5). Of the patients, 57% had daily headaches upon study entry, 71% had improved pain intensity from the first diary entry to the last diary entry, and 57% had complete headache resolution at an average of 7.6 days from medication discontinuation (SD = 5.1). Ibuprofen was the most overused medication (71%). Conclusions: Our findings suggest that medication overuse headache will improve in the majority of pediatric patients who abruptly stop the offending medication(s) in an average of 8 days from withdrawal. Average pain intensity was reduced by more than one point among all patients who stopped taking abortive medications. Further larger-scale studies on medication withdrawal in pediatric patients with medication overuse headache could help us better understand whether this management strategy is effective.
- 15 February 2022
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 23 (9) , 1536-1543
Natural History of Abortive Medication Withdrawal in the Management of Pediatric Medication Overuse Headache
Objective: The objective of this study is to document pain scores during withdrawal of abortive medication in patients diagnosed with medication overuse headache. Design: Cross-sectional study. Setting: Children’s National Hospital’s Headache Program. Subjects: Patients 6–18 years of age who presented to the Headache Clinic at Children’s National Hospital with presumed medication overuse headache between March 2017 and March 2019 were invited to participate. Methods: Patients were instructed to abruptly discontinue overused medications and record their headache characteristics daily in a diary for 8 weeks. Results: Fourteen diaries were returned and analyzed at a 4-week follow-up visit. Ninety-three percent of the patients were females, with a median age of 14.9 years (standard deviation [SD] = 2.0). The average headache intensity upon study entry was 4.7 out of 10 (SD = 2.5), and the average headache intensity upon study completion was 3.1 (SD = 2.5). Of the patients, 57% had daily headaches upon study entry, 71% had improved pain intensity from the first diary entry to the last diary entry, and 57% had complete headache resolution at an average of 7.6 days from medication discontinuation (SD = 5.1). Ibuprofen was the most overused medication (71%). Conclusions: Our findings suggest that medication overuse headache will improve in the majority of pediatric patients who abruptly stop the offending medication(s) in an average of 8 days from withdrawal. Average pain intensity was reduced by more than one point among all patients who stopped taking abortive medications. Further larger-scale studies on medication withdrawal in pediatric patients with medication overuse headache could help us better understand whether this management strategy is effective.